Product safety study for a citrate calcium anticoagulation system

Recruitment status	[X] Prospectively registered
No longer recruiting	☐ Protocol
Overall study status	Statistical analysis plan
Completed	Results
Condition category	Individual participant data
5	Record updated in last year
	No longer recruiting Overall study status

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Prof Dieter Falkenhagen

Contact details

Dr.-Karl-Dorrek-Str. 30 Krems Austria 3500

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers N/A

Study information

Scientific Title

Product safety study for a citrate calcium anticoagulation system: an interventional single-arm open-label trial

Study objectives

Primary goal of the study is the proof of functionality and safety of a algorithm for automated software controlled citrate-calcium anticoagulation. The hypothesis of the authors is that the specification of a target calcium value in the anticoagulated extracorporeal circuit is associated with a high functionality and a high safety using a citrate calcium anticoagulation.

Ethics approval required

Old ethics approval format

Ethics approval(s)

To be submitted to the Ethics Committee of Upper Austria, Wagner Jauregg Mental Health Hospital as of 04/02/2009.

Study design

Interventional single-arm open-label trial

Primary study design

Interventional

Secondary study design

Other

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

Health condition(s) or problem(s) studied

Chronic dialysis

Interventions

Regional anticoagulation with trinatrium citrate and substitution with calcium chloride. Five treatments per patient over 2 weeks, with a duration of 4 hours per treatment planned.

Intervention Type

Other

Phase

Not Applicable

Primary outcome measure

The following will be assessed at baseline, after 15 minutes and then every 60 minutes during treatment (maximum treatment duration is 4 hours):

- 1. Evaluation of the effectiveness of anticoagulation based on coagulation parameters
- 2. Time dependency of citrate and calcium values in the extracorporal circuit
- 3. Anticoagulation state in the extracorporal circuit
- 4. Citrate and calcium level in the patients blood

Secondary outcome measures

The following will be assessed at baseline and end of each treatment period: D-Dimer, Mg2+ and sodium concentration

Overall study start date

01/05/2009

Completion date

31/08/2009

Eligibility

Key inclusion criteria

1. Both males and females, age: 19 to 65 years

2. Chronic dialysis patients

3. Haematocrit (Hkt): 30 bis 45 %

4. Ca2+: 1.0-1.30 mmol/l

5. Weight: >60 kg

Participant type(s)

Patient

Age group

Adult

Sex

Both

Target number of participants

14

Key exclusion criteria

- 1. High risk of bleeding, pallets count <40,000/µl
- 2. Haemoglobin <9 g/dl
- 3. Alkalosis pH > 7.50
- 4. Acidosis pH < 7.35
- 5. Liver insufficiency
- 6. Respiratory insufficiency
- 7. Patients with cardiovascular problems
- 8. Oral anticoagulans
- 9. Hepatitis C, B, HIV patients

Date of first enrolment 01/05/2009

Date of final enrolment 31/08/2009

Locations

Countries of recruitment

Austria

Study participating centre Dr.-Karl-Dorrek-Str. 30 Krems Austria 3500

Sponsor information

Organisation

Danube University Krems (Austria)

Sponsor details

Dr.-Karl-Dorrek-Str. 30 Krems Austria 3500

Sponsor type

University/education

Website

http://www.donau-uni.ac.at

ROR

https://ror.org/03ef4a036

Funder(s)

Funder type

University/education

Funder Name

Danube University Krems (Austria)

Results and Publications

Publication and dissemination planNot provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summaryNot provided at time of registration